Skip to main content
. 2021 Jul 21;12:704276. doi: 10.3389/fpsyt.2021.704276

Table 1.

Subjects' characteristics and lifetime substances use pattern (n = 316) (n, %).

Sex Male 248 (78.5%)
Age (years) Mean (SD) 37.47 (±8.65)
Minimum–Maximum 19–65 years
Body mass index (kg/m2) <21.0 80 (26.1%)
21.0–24.99 132 (43.1%)
≥25.0 94 (30.7%)
Missing 10
Academic attainment < High school degree 88 (27.8%)
High school degree 93 (29.4%)
Graduate degree 135 (42.7%)
Frequency of cocaine use during the worst period Daily 190 (60.1%)
1–6 use by week 78 (24.7%)
Less than weekly 48 (15.2%)
Length of regular cocaine use (year) Median (Minimum–Maximum) 5 (1–34)
1st quartile; 3rd quartile 2.5; 11
Crack use (vs. cocaine hydrochloride) Yes 88 (27.8%)
Preferred route of cocaine use: Smoked or/and intravenous 121 (38.3%)
Intranasal (sniffed) 195 (61.7%)
History of intravenous cocaine use Yes 85 (26.9%)
Missing 1
Age of cocaine first use (years) Mean (SD) 23.4 (±7.3)
Median (Minimum–Maximum) 21.0 years (12–53)
Opioid use and opioid maintenance treatment (OMT) Never 103 (32.7%)
Opioid use without OMT 72 (22.9%)
OMT use 140 (44.4%)
Missing 1
Amphetamine use during the worst period Never 124 (39.9%)
Non-daily use 131 (42.1%)
Daily use 56 (18.0%)
Missing 5
Tobacco use Less than daily use 19 (6.0%)
Daily use 296 (94.0%)
Missing 1
Lifetime alcohol use* No dependence 114 (36.8%)
Dependence 196 (63.2%)
Missing 6
Lifetime cannabis use* No dependence 121 (38.8%)
Dependence 191 (61.2%)
Missing 4
ALDH2 rs2238151 genotype (N = 96, sample restricted to patients with lifetime CACP history) CC 19 (19.8%)
CT 34 (35.4%)
TT 43 (44.8%)
ALDH2 rs2238151 genotype (N = 76, sample restricted to patients with lifetime CACP history and European Ancestry) CC 9 (11.8%)
CT 30 (39.5%)
TT 37 (48.7%)
*

Dependence according to DSM IV -TR criteria.